Brean Capital Lowers Baxano Surg Price Target to $3.50 (BAXS)
Research analysts at Brean Capital decreased their price target on shares of Baxano Surg (NASDAQ:BAXS) from $4.00 to $3.50 in a report released on Friday, Stock Ratings Network.com reports. Brean Capital’s target price would suggest a potential upside of 409.46% from the stock’s previous close.
Baxano Surg (NASDAQ:BAXS) opened at 0.687 on Friday. Baxano Surg has a one year low of $0.66 and a one year high of $2.50. The stock has a 50-day moving average of $0.97 and a 200-day moving average of $1.1. The company’s market cap is $32.4 million.
Baxano Surg (NASDAQ:BAXS) last released its earnings data on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.07. Analysts expect that Baxano Surg will post $-0.47 EPS for the current fiscal year.
Baxano Surgical Inc, formerly TranS1 Inc, is a medical device company focused on designing, developing and marketing products that implement its approach to treat degenerative conditions of the spine affecting the lower lumbar region.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.